Key Points
- Director Christopher David Taves sold 176,786 shares of MediPharm Labs on June 9 at an average price of C$0.08, worth about C$14,142.88.
- After the transaction, Taves still held 2,847,939 shares, and the sale reduced his ownership by 5.84%.
- MediPharm Labs shares were trading at C$0.08, with a market cap of C$31.86 million and a 12-month range of C$0.06 to C$0.10.
MediPharm Labs Corp. (TSE:LABS - Get Free Report) Director Christopher David Taves sold 176,786 shares of MediPharm Labs stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of C$0.08, for a total value of C$14,142.88. Following the sale, the director owned 2,847,939 shares in the company, valued at C$227,835.12. This trade represents a 5.84% decrease in their ownership of the stock.
MediPharm Labs Stock Performance
Shares of MediPharm Labs stock opened at C$0.08 on Friday. The business's fifty day simple moving average is C$0.08 and its 200 day simple moving average is C$0.07. The firm has a market capitalization of C$31.86 million, a P/E ratio of -3.75 and a beta of -0.61. MediPharm Labs Corp. has a 12 month low of C$0.06 and a 12 month high of C$0.10. The company has a current ratio of 3.02, a quick ratio of 3.10 and a debt-to-equity ratio of 0.05.
About MediPharm Labs
(
Get Free Report)
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products produced in a GMP-certified facility with ISO-standard clean rooms. MediPharm has invested in an expert research-driven team, state-of-the-art technology, advanced purification methodologies, and purpose-built facilities to deliver pure, trusted, precision-dosed cannabinoid products for domestic and international markets.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
